Discovery of Ixabepilone
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The discovery of the antineoplastic agent paclitaxel and its unique activity as a microtubule-stabilizing agent resulted in dramatic improvements in the treatment of breast, ovarian, and non-small cell lung cancers. Despite the potent antitumor activity of taxanes such as paclitaxel, efficacy of these agents has been limited by development of taxane-resistant tumors in patients. This review describes, with some historical context, our successful efforts to discover a next-generation microtubule-stabilizing agent for the treatment of cancer. In collaboration with the Gesellschaft für Biotechnologische Forschung, we evaluated the epothilones, originally isolated from the myxobacterium Sorangium cellulosum, as potential anticancer agents. Experiments performed at Bristol-Myers Squibb confirmed the ability of these agents to induce tubulin polymerization, cell cycle arrest, and apoptosis. Epothilones A and B showed potent cytotoxic activity toward paclitaxel-sensitive and paclitaxel-resistant cells expressing P-glycoprotein or mutant tubulin. Because the parent epothilones were subject to inactivation via esterase cleavage, we used semisynthetic approaches to prepare analogues without this liability. BMS-247550 (ixabepilone), the lactam analogue of epothilone B, showed increased metabolic stability, potent tubulin polymerization activity, and retained activity against paclitaxel-resistant lines. Based on its shown efficacy in clinical trials, ixabepilone was approved by the Food and Drug Administration in 2007 for treatment of drug-resistant/refractory metastatic or locally advanced breast cancer. [Mol Cancer Ther 2009;8(2):275–81]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600 · cited 1×
“Following the original discovery of paclitaxel (1) and the elucidation of its unique mechanism of action as a microtubule-stabilizing agent (2), BMS, working closely with the National Cancer Institute, had developed paclitaxel into a mainstay therapy for breast, non-small cell lung, and other tumors.”
BackgroundInfluentialDiscodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol,
ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., & Day, B. W. (1996) · Biochemistry · doi:10.1021/bi9515127 · Cited by 382 · cited 1×
“In early 1996, two groups independently reported that the G2-M block produced by discodermolide is a result of its ability to polymerize microtubules (12, 13).”
BackgroundDISCODERMOLIDE—A NEW, MARINE-DERIVED IMMUNOSUPPRESSIVE COMPOUND: I. IN VITRO STUDIES
LONGLEY, R. E., CADDIGAN, D., HARMODY, D., GUNASEKERA, M., & GUNASEKERA, S. P. (1991) · Transplantation · doi:10.1097/00007890-199110000-00014 · Cited by 104
Cited by
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Macrocycles In New Drug Discovery
Mallinson, J., & Collins, I. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.93 · Cited by 468
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401
“As a comparison, we have also examined in PS19 mice the drug ixabepilone (Ixempra), which is another member of the epothilone family of MT-stabilizing drugs that is currently approved for the treatment of metastatic breast cancer (Hunt, 2009).”
BackgroundThe modification of natural products for medical use
Guo, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.003 · Cited by 328
Myxobacterial secondary metabolites: bioactivities and modes-of-action
Weissman, K. J., & Müller, R. (2010) · Natural Product Reports · doi:10.1039/c001260m · Cited by 310
Metadata
- Authors
- Hunt, J. T.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 275-281
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2124038924
- Cited by
- 105
- References
- 3
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of Ixabepilone. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0999
- The paper
- Hunt, J. T. (2009). Discovery of Ixabepilone. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.